Current Report Filing (8-k)
March 16 2015 - 4:08PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): March 10, 2015
SEQUENOM, INC.
(Exact
Name of Registrant as Specified in Charter)
|
|
|
|
|
DELAWARE |
|
000-29101 |
|
77-0365889 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
3595 JOHN HOPKINS COURT
SAN DIEGO, CALIFORNIA 92121
(Address of Principal Executive Offices)
(858) 202-9000
(Registrants telephone number, including area code)
N/A
(Former name or
former address, if changed since last report)
Check the
appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
(d) On March 10, 2015, our Board of Directors elected Dirk van den Boom, Ph.D., our
current Executive Vice President, Chief Scientific and Strategy Officer, as a director, effective April 1, 2015. In addition, our Board of Directors appointed Dr. van den Boom to the Science Committee of our Board of Directors, also
effective April 1, 2015. Dr. van den Boom will fill the vacancy created by the resignation of Harry F. Hixson, Jr., Ph.D. as a director, which resignation is effective March 31, 2015. We are not aware of any transaction requiring
disclosure under Item 404(a) of Regulation S-K.
2.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
SEQUENOM, INC. |
|
|
|
Date: March 16, 2015 |
|
By: |
|
/s/ Jeffrey D. Linton |
|
|
|
|
Jeffrey D. Linton |
|
|
|
|
Senior Vice President, General Counsel & Secretary |
3.
Sequenom, Inc. (NASDAQ:SQNM)
Historical Stock Chart
From May 2024 to Jun 2024
Sequenom, Inc. (NASDAQ:SQNM)
Historical Stock Chart
From Jun 2023 to Jun 2024